The Medical Technology Stock Letter currently covers the companies listed below. The majority of our portfolio have been long-term investments; MTSL consistently adds new independent recommendations (e.g., MDGL and ESPR were new ideas in 2016 and 2017, respectively). Click on the company name for general information about the company, our CEO insight, a link to the company pipeline and government registry and results database on completed, ongoing and planned clinical trials.
Portfolio company updates are our analysis of key recent and upcoming near-term events and catalysts specific to each company, accompanied by our BUY LIMIT and TARGET PRICE. In-depth coverage and complete updates of the companies in our portfolio are available only to MTSL subscribers.*
Ticker |
Company |
Updates |
| ACAD | Acadia | Get latest update |
| TCRT** | Alaunos Therapeutics | Get latest update |
| ALKS | Alkermes | Get latest update |
| BCYC | Bicycle Therapeutics | Get latest update |
| BMRN | BioMarin | Get latest update |
| CLDX | Celldex | Get latest update |
| ESPR | Esperion | Get latest update |
| INCY | Incyte | Get latest update |
| IONS | Ionis | Get latest update |
| MDGL | Madrigal | Get latest update |
| PCRX | Pacira | Get latest update |
| PGEN | Precigen | Get latest update |
| SGMO | Sangamo | Get latest update |
| SKYE | Skye Bioscience | Get latest update |
| VXRT | Vaxart | Get latest update |
| VKNG | Viking | Get latest update |
*Disclaimer
**ZIOP changed name to Alaunos Therapeutics (TCRT) in Feb. 2022